Validation of the Prognostic Stage of American Joint Committee on Cancer Eighth Edition Staging Manual in Invasive Lobular Carcinoma Compared to Invasive Ductal Carcinoma and Proposal of a Novel Score System

Ding, Shuning; Zong, Yu; Lin, Caijin; Andriani, Lisa; Chen, Weilin; Liu, Deyue; Chen, Weiguo; Li, Yafen; Shen, Kunwei; Wu, Jiayi; Zhu, Li

doi:10.3389/fonc.2020.01471

Cited by 9 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis of ILC was similar to that of IDC in general, and a histologically high-risk subset of ILC based on the Ki-67 and/or histological grade, and ER status was reported previously [16,17]. We did not perform this type of grading for ILC because, currently, a diagnosis of ILC is almost selectively given for classical type ILC alone in Japan, and is usually classified as NG1.…”

Section: Discussionsupporting

confidence: 65%

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

et al. 2022

View full text Add to dashboard Cite

Background This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institutional randomized N·SAS-BC 01 trial, where the efficacy of adjuvant chemotherapy regimens was evaluated in 733 high-risk node-negative invasive breast cancer patients. Methods Of 545 patients with long-term follow-up data (median 12.1 years), pathology slides, and local pathology diagnosis, 530 eligible patients were subjected to central pathology review (CPR) for histological type and nuclear grade (NG). Concordance in NGs was compared with local diagnosis. The 10/15-year recurrence-free survival (RFS) and overall survival (OS) rates stratified by NG and histological type were calculated. Results Local diagnoses were invasive ductal carcinoma (IDC)-NG2, IDC-NG3, invasive lobular carcinoma (ILC), and metaplastic carcinoma (MC) in 158/327/38/7 patients, respectively. The 10/15-year RFS rates were 87.2/82.6% for IDC-NG2 and 81.8/75.0% for IDC-NG3 (p = 0.061), and OS rates were 95.0/92.8% for IDC-NG2 and 90.8/85.7% for IDC-NG3 (p = 0.042). CPR graded 485 locally diagnosed IDCs as IDC-NG1/NG2/NG3/unknown in 98/116/267/4 patients, respectively. No significant difference was found among survival curves for the three NG groups. Although the agreement level between local and CPR diagnoses was low (κ = 0.311), both diagnoses identified a patient group with a 15-year recurrence rate ≥ 20%. The 10/15-year RFS rates were 79.4/63.5% for ILC and 68.6%/unknown for MC. Conclusions The N·SAS grading system identified a patient group with high-risk node-negative invasive breast cancer, suggesting that local diagnosis was performed efficiently in the N·SAS-BC 01 trial. Trial registration number: UMIN000022571. Date of registration: June 1, 2016.

show abstract

Section: Discussionsupporting

confidence: 65%

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…According to the results of clinical data analysis of BC tissues in the TCGA, the expression level of ZNF775 in patients with ILC was signi cantly higher than that of IDC. At present, the most common histological types of BC are IDC and ILC among which IDC accounts for 70%-75%, and ILC accounts for about 10% of all cases [45] . One study found that among 16,703 patients with metastatic BC in the ESME database, patients with ILC had poorer overall survival and PFS1 compared to patients with IDC [45] .…”

Section: Discussionmentioning

confidence: 99%

“…At present, the most common histological types of BC are IDC and ILC among which IDC accounts for 70%-75%, and ILC accounts for about 10% of all cases [45] . One study found that among 16,703 patients with metastatic BC in the ESME database, patients with ILC had poorer overall survival and PFS1 compared to patients with IDC [45] .…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Suicide or self-preservation：C2H2 Zinc Finger Protein ZNF775 inhibits MCF-7 breast cancer cell migration by downregulating Wnt5a

Zhu,

Gong,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

C2H2 zinc finger protein is widely involved in the occurrence and development of cancer. However, the function and mechanism of most C2H2 zinc finger proteins in breast caner (BC) remains unclear. Here, we reported the expression prognosis of C2H2 type zinc finger protein ZNF775 in BC patients and its possible biological mechanism. First, multiple public databases showed that ZNF775 was significantly overexpressed in BC tissues and cells. Interestingly, high expression of ZNF775 was significantly associated with a better prognosis. Western blot and immunohistochemistry were used for verification, and the expression of ZNF775 was consistent with the databases. In vitro overexpression experiments showed that overexpression of ZNF775 significantly inhibited the proliferation and migration of MCF-7 BC cell. We further combined RNA-sequencing (RNA-seq) and CUT & Tag, and found that overexpression of ZNF775 can down-regulate the expression of most genes in the Wnt signaling pathway. The cBioportal database showed that ZNF775 was negatively correlated with the expression of Wnt5a, suggesting that its downstream target was likely Wnt5a. Finally, we discovered that Wnt5a could partially reverse the inhibitory effect of ZNF775 on MCF-7 BC cell migration through transwell migration experiments. In conclusion, our findings will provide new ideas for the diagnosis, treatment and prognosis assessment of BC in the future.

show abstract

“…[2][3][4][5] Therefore, the 8th edition AJCC staging system incorporated the prognostic biomarkers ER, PR, HER2 and HG, and multigene assays when available to form the prognostic staging system (PS). Since the publication of the 8th edition AJCC staging system, the PS has repeatedly been validated and proved superior to the AS in Western [6][7][8][9] and Asian populations. 10,11 Nevertheless, the prognostic value of PS for breast cancer based on molecular subtype has rarely been explored.…”

Section: Introductionmentioning

confidence: 99%

“…Since the 8th edition AJCC PS manual has been published for more than three years, most studieds have validated its superiority over AS. [6][7][8][9][10][11] To the best of our knowledge, only a few studies have investigated the value of PS in different molecular subtypes. In a retrospective study of 170 HER2-enriched breast cancers, Zhou et al found that both AS and PS had prognostic value in this subtype of breast cancer.…”

mentioning

confidence: 99%

Validation of the Prognostic Stage from the American Joint Committee on Cancer 8th Staging Manual in Luminal B-Like Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Ding¹,

Jiang²,

Xu³

et al. 2022

CMAR

View full text Add to dashboard Cite

The 8th edition American Joint Committee on Cancer (AJCC) prognostic staging system (PS) has been validated numerous times; however, the prognostic value of PS for breast cancer based on molecular subtype has rarely been explored. This study aimed to investigate the prognostic value of PS in Chinese patients with luminal B-like human epidermal growth factor receptor 2 (HER2)negative breast cancer. Methods: A total of 407 eligible cases were included in the study. All of the cases were restaged using the 8th edition AJCC Anatomic Staging System (AS) and PS. The Kaplan-Meier method was used to calculate estimated survival and the Log rank test was used to compare the survival differences between groups. Results:The 5-year disease-specific survival (DSS) and overall survival (OS) rates were 90.3% and 93.5%, respectively, and there were statistically significant differences in the 5-year DSS and 5-year OS rates among the different anatomic and prognostic stage groups. The application of the PS resulted in the assignment of 215 (52.8%) patients to a different group. Different prognostic stage groups restaged from anatomic Stage III had significant differences in both DSS (χ 2 = 4.366, p = 0.037) and OS (χ 2 = 7.549, p = 0.006); additionally, different prognostic stage groups from the anatomic Stage II group had significant differences in DSS (χ 2 = 7.724, p = 0.021) but no significant differences in OS (χ 2 = 5.182, p = 0.075). However, different prognostic stage groups from anatomic Stage I had no significant differences in either DSS (χ 2 = 0.159, p = 0.690) or OS (χ 2 = 0.099, p = 0.753). Conclusion:The 8th edition AJCC PS refined the anatomic stage grouping in luminal B-like HER2-negative breast cancer and could lead to a more personalized approach to breast cancer treatment.

show abstract

Validation of the Prognostic Stage of American Joint Committee on Cancer Eighth Edition Staging Manual in Invasive Lobular Carcinoma Compared to Invasive Ductal Carcinoma and Proposal of a Novel Score System

Cited by 9 publications

References 28 publications

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

WITHDRAWN: Suicide or self-preservation：C2H2 Zinc Finger Protein ZNF775 inhibits MCF-7 breast cancer cell migration by downregulating Wnt5a

Validation of the Prognostic Stage from the American Joint Committee on Cancer 8th Staging Manual in Luminal B-Like Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Contact Info

Product

Resources

About